Access the full text.
Sign up today, get DeepDyve free for 14 days.
H. Timmins, D. Mizrahi, Tiffany Li, M. Kiernan, D. Goldstein, Susanna Park (2021)Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review
Journal of Cancer Survivorship, 17
T. Postma, N. Aaronson, J. Heimans, M. Muller, J. Hildebrand, J. Delattre, K. Hoang-Xuan, M. Lanteri-Minet, R. Grant, R. Huddart, C. Moynihan, J. Maher, R. Lucey (2005)The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20.
European journal of cancer, 41 8
Zachary Veitch, O. Khan, D. Tilley, P. Tang, D. Ribnikar, D. Stewart, X. Kostaras, K. King, S. Lupichuk (2019)Impact of Cumulative Chemotherapy Dose on Survival With Adjuvant FEC-D Chemotherapy for Breast Cancer.
Journal of the National Comprehensive Cancer Network : JNCCN, 17 8
D. Rivera, P. Ganz, M. Weyrich, H. Bandos, J. Melnikow (2018)Chemotherapy-Associated Peripheral Neuropathy in Patients With Early-Stage Breast Cancer: A Systematic Review.
Journal of the National Cancer Institute, 110 2
T. Kus, G. Aktas, M. Kalender, A. Sevinç, S. Kul, A. Suner, Esra Ulker, Celaletdin Camcı (2016)Taxane-induced peripheral sensorial neuropathy in cancer patients is associated with duration of diabetes mellitus: a single-center retrospective study
Supportive Care in Cancer, 24
K. Webster, D. Cella, K. Yost (2003)The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation
Health and Quality of Life Outcomes, 1
G. Cavaletti, S. Jann, A. Pace, R. Plasmati, G. Siciliano, C. Briani, D. Cocito, L. Padua, E. Ghiglione, M. Manicone, G. Giussani (2006)Multi‐center assessment of the Total Neuropathy Score for chemotherapy‐induced peripheral neurotoxicity
Journal of the Peripheral Nervous System, 11
(2007)Overweight and obesity in adults in Australia: a snapshot
W. Dijksterhuis, M. Pruijt, S. Woude, R. Klaassen, S. Kurk, M. Oijen, H. Laarhoven (2019)Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy
Journal of Cachexia, Sarcopenia and Muscle, 10
K. Winters-Stone, F. Horak, P. Jacobs, Phoebe Trubowitz, N. Dieckmann, S. Stoyles, S. Faithfull (2017)Falls, Functioning, and Disability Among Women With Persistent Symptoms of Chemotherapy-Induced Peripheral Neuropathy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 23
DR Cornblath, V Chaudhry, K Carter, D Lee, M Seysedadr, M Miernicki, T Joh (1999)Total neuropathy score: validation and reliability study
Natalie Simon, M. Danso, T. Alberico, E. Basch, A. Bennett (2017)The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice
Quality of Life Research, 26
Susanna Park, C. Lin, A. Krishnan, D. Goldstein, M. Friedlander, M. Kiernan (2011)Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility.
The oncologist, 16 5
Susanna Park, D. Goldstein, A. Krishnan, C. Lin, M. Friedlander, J. Cassidy, M. Koltzenburg, M. Kiernan (2013)Chemotherapy‐induced peripheral neurotoxicity: A critical analysis
CA: A Cancer Journal for Clinicians, 63
B. Callaghan, R. Xia, M. Banerjee, N. Rekeneire, T. Harris, A. Newman, S. Satterfield, A. Schwartz, A. Vinik, E. Feldman, E. Strotmeyer (2016)Metabolic Syndrome Components Are Associated With Symptomatic Polyneuropathy Independent of Glycemic Status
C. Fryar, D. Kruszon-Moran, Q. Gu, C. Ogden (2018)Mean Body Weight, Height, Waist Circumference, and Body Mass Index Among Adults: United States, 1999-2000 Through 2015-2016.
National health statistics reports, 122
M. Barginear, A. Dueck, J. Allred, C. Bunnell, H. Cohen, R. Freedman, A. Hurria, G. Kimmick, J. Le-Rademacher, S. Lichtman, H. Muss, L. Shulman, M. Copur, D. Biggs, B. Ramaswamy, J. Lafky, A. Jatoi (2018)Age and the Risk of Paclitaxel‐Induced Neuropathy in Women with Early‐Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101
The Oncologist, 24
B. Schneider, Fengmin Zhao, Molin Wang, V. Stearns, S. Martino, V. Jones, E. Perez, T. Saphner, A. Wolff, G. Sledge, W. Wood, N. Davidson, J. Sparano (2012)Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 25
H. Timmins, Tiffany Li, W. Huynh, M. Kiernan, S. Baron-Hay, F. Boyle, D. Goldstein, Susanna Park (2020)Electrophysiological and phenotypic profiles of taxane-induced neuropathy
Clinical Neurophysiology, 131
H. Timmins, Tiffany Li, M. Kiernan, S. Baron-Hay, G. Marx, F. Boyle, D. Goldstein, Susanna Park (2020)Taxane-induced peripheral neuropathy: differences in patient report and objective assessment
Supportive Care in Cancer, 28
K. Alberti, R. Eckel, S. Grundy, P. Zimmet, J. Cleeman, K. Donato, J. Fruchart, W. James, C. Loria, Sidney Smith (2009)Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As
Circulation, 120 16
B. Callaghan, Evan Reynolds, M. Banerjee, Ericka Chant, Emily Villegas-Umana, E. Feldman (2020)Central Obesity is Associated With Neuropathy in the Severely Obese.
Mayo Clinic proceedings, 95 7
JM McCrary, D Goldstein, T Trinh, HC Timmins, T Li, J Menant (2019)Balance deficits and functional disability in cancer survivors exposed to neurotoxic cancer treatments
J Natl Compr Cancer Netw, 17
A. Ottaiano, A. Nappi, S. Tafuto, G. Nasti, C. Divitiis, C. Romano, A. Cassata, R. Casaretti, L. Silvestro, A. Avallone, Maurizio Capuozzo, M. Capozzi, P. Maiolino, V. Quagliariello, S. Scala, V. Iaffaioli (2016)Diabetes and Body Mass Index Are Associated with Neuropathy and Prognosis in Colon Cancer Patients Treated with Capecitabine and Oxaliplatin Adjuvant Chemotherapy
S. Song, Jinny Min, S. Suh, S. Jung, H. Hahn, S. Im, Ju-Yeun Lee (2017)Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer
Supportive Care in Cancer, 25
J. McCrary, D. Goldstein, Carolina Sandler, Carolina Sandler, Carolina Sandler, B. Barry, B. Barry, Michael Marthick, H. Timmins, Tiffany Li, L. Horvath, Lisa Horvath, P. Grimison, P. Grimison, Susanna Park, Susanna Park (2019)Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy
Supportive Care in Cancer
Z Veitch, OF Khan, D Tilley, PA Tang, D Ribnikar, DA Stewart (2019)Impact of cumulative chemotherapy dose on survival with adjuvant FEC-D chemotherapy for breast cancer
J Natl Compr Cancer Netw, 17
S. Gérard, D. Brechemier, A. Lefort, S. Lozano, G. Kan, T. Filleron, L. Mourey, C. Bernard‐Marty, M. Rougé-Bugat, V. Soler, B. Vellas, M. Cesari, Y. Rolland, L. Balardy (2015)Body composition and anti-neoplastic treatment in adult and older subjects - A systematic review
The journal of nutrition, health & aging, 20
Iva Petrovchich, K. Kober, L. Wagner, S. Paul, G. Abrams, M. Chesney, K. Topp, Betty Smoot, M. Schumacher, Y. Conley, M. Hammer, J. Levine, C. Miaskowski (2019)Deleterious Effects of Higher Body Mass Index on Subjective and Objective Measures of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors.
Journal of pain and symptom management
Christopher Frames, Rahul Soangra, T. Lockhart, J. Lach, D. Ha, K. Roberto, A. Lieberman (2018)Dynamical Properties of Postural Control in Obese Community-Dwelling Older Adults †
Sensors (Basel, Switzerland), 18
K Alberti, RH Eckel, SM Grundy, PZ Zimmet, JI Cleeman, KA Donato, JC Fruchart, WP James, CM Loria, SC Smith (2009)Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity
S. Swain, J. Arezzo (2008)Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management.
Clinical advances in hematology & oncology : H&O, 6 6
E. Davidson, L. Coppey, N. Calcutt, C. Oltman, M. Yorek (2010)Diet‐induced obesity in Sprague–Dawley rats causes microvascular and neural dysfunction
Diabetes/Metabolism Research and Reviews, 26
D. Sturnieks, R. Arnold, S. Lord (2011)Validity and reliability of the Swaymeter device for measuring postural sway
BMC Geriatrics, 11
E. Calhoun, E. Welshman, Chih-Hung Chang, J. Lurain, D. Fishman, T. Hunt, D. Cella (2003)Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (Fact/GOG‐Ntx) questionnaire for patients receiving systemic chemotherapy
International Journal of Gynecological Cancer, 13
N. Klöting, M. Blüher (2014)Adipocyte dysfunction, inflammation and metabolic syndrome
Reviews in Endocrine and Metabolic Disorders, 15
Justin Brown, Sui Zhang, F. Ou, A. Venook, D. Niedzwiecki, H. Lenz, F. Innocenti, B. O'Neil, J. Shaw, B. Polite, C. Denlinger, J. Atkins, R. Goldberg, K. Ng, R. Mayer, C. Blanke, E. O’Reilly, C. Fuchs, J. Meyerhardt (2019)Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance)
JNCI Cancer Spectrum, 4
P. Zimmer, Sina Trebing, Ursula Timmers-Trebing, A. Schenk, R. Paust, W. Bloch, R. Rudolph, F. Streckmann, F. Baumann (2018)Eight-week, multimodal exercise counteracts a progress of chemotherapy-induced peripheral neuropathy and improves balance and strength in metastasized colorectal cancer patients: a randomized controlled trial
Supportive Care in Cancer, 26
D. Hershman, C. Till, J. Wright, D. Awad, S. Ramsey, W. Barlow, L. Minasian, J. Unger (2016)Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 25
Jetter Robertson, J. Raizer, J. Hodges, William Gradishar, Jeffrey Allen (2018)Risk factors for the development of paclitaxel‐induced neuropathy in breast cancer patients
Journal of the Peripheral Nervous System, 23
DL Hershman, C Lacchetti, RH Dworkin, EM Lavoie Smith, J Bleeker, G Cavaletti, C Chauhan, P Gavin, A Lavino, MB Lustberg, J Paice, B Schneider, ML Smith, T Smith, S Terstriep, N Wagner-Johnston, K Bak, CL Loprinzi (2014)Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline
J Clin Oncol, 32
Phillipe O'Brien, L. Hinder, B. Callaghan, E. Feldman (2017)Neurological consequences of obesity
The Lancet Neurology, 16
S. Schmidt, R. Oliveira, F. Rocha, Y. Abreu-Villaça (2000)Influences of Handedness and Gender on the Grooved Pegboard Test
Brain and Cognition, 44
DL Sturnieks, R Arnold, SR Lord (2011)Validity and reliability of the Swaymeter device for measuring postural sway.(Technical advance)(Report)
BMC Geriatr, 11
H. Greenlee, D. Hershman, Zaixing Shi, M. Kwan, I. Ergas, Janise Roh, L. Kushi (2017)BMI, Lifestyle Factors and Taxane‐Induced Neuropathy in Breast Cancer Patients: The Pathways Study
Journal of the National Cancer Institute, 109
Chaoyang Li, E. Ford, L. Mcguire, A. Mokdad (2007)Increasing Trends in Waist Circumference and Abdominal Obesity among U.S. Adults
B. Callaghan, R. Xia, Evan Reynolds, M. Banerjee, A. Rothberg, C. Burant, Emily Villegas-Umana, R. Pop-Busui, E. Feldman (2016)Association Between Metabolic Syndrome Components and Polyneuropathy in an Obese Population.
JAMA neurology, 73 12
Raafia Ali, V. Baracos, M. Sawyer, L. Bianchi, S. Roberts, E. Assenat, C. Mollevi, P. Senesse (2016)Lean body mass as an independent determinant of dose‐limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens
Cancer Medicine, 5
E. Basch, A. Iasonos, T. McDonough, A. Barz, A. Culkin, M. Kris, H. Scher, D. Schrag (2006)Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study.
The Lancet. Oncology, 7 11
(2014)Obesity in adults: prevalence, screening, and evaluation. UpToDate
(2000)Obesity : preventing andmanaging the global epidemic . Report of aWHO consultation
E. Calhoun, E. Welshman, C.-H. Chang, J. Lurain, D. Fishman, T. Hunt, D. Cella (2003)Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy
International Journal of Gynecologic Cancer, 13
J. Li, Jian Tang, Ying-jie Li, Jianqi Yu, Baoshi Zhang, Changhai Yu (2015)Pharmacokinetic profile of paclitaxel in the plasma, lung, and diaphragm following intravenous or intrapleural administration in rats
Thoracic Cancer, 6
A. Argyriou, Susanna Park, B. Islam, Stefano Tamburin, R. Velasco, P. Alberti, J. Bruna, D. Psimaras, G. Cavaletti, D. Cornblath (2019)Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings
Journal of Neurology, Neurosurgery, and Psychiatry, 90
R. Ross, I. Neeland, S. Yamashita, I. Shai, J. Seidell, P. Magni, R. Santos, B. Arsenault, A. Cuevas, F. Hu, B. Griffin, A. Zambon, P. Barter, J. Fruchart, R. Eckel, Y. Matsuzawa, J. Despres (2020)Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity
Nature Reviews. Endocrinology, 16
D. Hershman, J. Unger, K. Crew, C. Till, H. Greenlee, L. Minasian, C. Moinpour, D. Lew, L. Fehrenbacher, J. Wade, Siu-Fun Wong, M. Fisch, N. Henry, K. Albain (2018)Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715)
JNCI: Journal of the National Cancer Institute, 110
I. Kleckner, C. Kamen, J. Gewandter, N. Mohile, C. Heckler, E. Culakova, C. Fung, M. Janelsins, M. Asare, P. Lin, P. Reddy, J. Giguere, J. Berenberg, S. Kesler, K. Mustian (2018)Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial
Supportive Care in Cancer, 26
J. Furlanetto, W. Eiermann, F. Marmé, T. Reimer, M. Reinisch, S. Schmatloch, Elmar Stickeler, C. Thomssen, Michael Untch, Carsten Denkert, G. Minckwitz, B. Lederer, V. Nekljudova, K. Weber, S. Loibl, Volker Möbus (2016)Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study.
Annals of oncology : official journal of the European Society for Medical Oncology, 27 11
D. Cornblath, V. Chaudhry, Kerryn Carter, D. Lee, M. Seysedadr, M. Miernicki, T. Joh (1999)Total neuropathy score
J. McCrary, D. Goldstein, T. Trinh, H. Timmins, Tiffany Li, J. Menant, M. Friedlander, C. Lewis, M. Hertzberg, Siobhan O’Neill, Tracy King, Annmarie Bosco, M. Harrison, Susanna Park (2019)Balance Deficits and Functional Disability in Cancer Survivors Exposed to Neurotoxic Cancer Treatments.
Journal of the National Comprehensive Cancer Network : JNCCN, 17 8
C. Loprinzi, C. Lacchetti, J. Bleeker, G. Cavaletti, C. Chauhan, D. Hertz, M. Kelley, A. Lavino, M. Lustberg, J. Paice, B. Schneider, Ellen Smith, M. Smith, Thomas Smith, N. Wagner-Johnston, D. Hershman (2020)Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
T. Rankinen, K. Sy, L. Pérusse, J. Despres, C. Bouchard (1999)The prediction of abdominal visceral fat level from body composition and anthropometry: ROC analysis
International Journal of Obesity, 23
(2018)International Association for the Study of Obesity
The Grants Register 2019
M. Blüher (2019)Obesity: global epidemiology and pathogenesis
Nature Reviews Endocrinology, 15
Z. Ghoreishi, S. Keshavarz, M. jafarabadi, Z. Fathifar, K. Goodman, A. Esfahani (2018)Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer
BMC Cancer, 18
S. Park, J. Kwok, R. Asher, C. Lee, P. Beale, F. Selle, M. Friedlander (2017)Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial.
Annals of oncology : official journal of the European Society for Medical Oncology, 28 11
H. Wildiers, M. Reiser (2011)Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma.
Critical reviews in oncology/hematology, 77 3
R. Mosteller (1987)Simplified calculation of body-surface area.
The New England journal of medicine, 317 17
Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
DL Hershman, JM Unger, KD Crew, C Till, H Greenlee, LM Minasian, CM Moinpour, DL Lew, L Fehrenbacher, JL Wade, SF Wong, MJ Fisch, N Lynn Henry, KS Albain (2018)Two-year trends of taxane-induced neuropathy in women enrolled in a randomized trial of acetyl-L-carnitine (SWOG S0715)
J Natl Cancer Inst, 110
(2000)Report of a WHO consultation. World Health Organization technical report series
PurposeChemotherapy-induced peripheral neuropathy (CIPN) is a major side effect of neurotoxic cancer treatment, often impacting treatment tolerability and patient functioning. Factors predicting an individual’s vulnerability for developing CIPN remain ill-defined. However, patient characteristics may contribute to CIPN risk, with obesity being a prevalent patient comorbidity. This study was aimed at evaluate if being overweight (BMI ≥ 25 kg/m2) was associated with worse symptomatic, clinical, and functional CIPN following neurotoxic cancer treatment.MethodsThree hundred seventy-nine cancer survivors were assessed 5 (IQR 3–5) months post oxaliplatin or paclitaxel treatment via comprehensive patient-reported, clinical, and functional CIPN measures. Patients classified as overweight (BMI ≥ 25 kg/m2) were compared to those within the normal BMI range (< 25 kg/m2). Multilinear regression was conducted to evaluate the association between patient clinical factors and CIPN severity.ResultsMost patients reported CIPN symptoms (78%), with deficits evident on clinical examination. Overweight patients (n = 242, 63.8%) had significantly worse CIPN across symptomatic, objective clinical, and functional outcomes compared to those with a normal BMI (p < .05). In multivariate linear regression, older age (B = .088, 95%CI = .053–.122, p < .001), larger waist circumference (B = .030, 95%CI = .001–.059, p < .05), and larger BSA (B = 2.41, 95%CI = .34–04.48, p < .05) were associated with CIPN. Diabetes and BMI were significant on univariate analysis but not in the final models.ConclusionsOverweight patients represent a large proportion of cancer survivors who may be particularly impacted by CIPN, requiring closer monitoring and referral to supportive services. Accessible data such as a patient’s general and abdominal obesity status may aid in formulating personalized treatment.Implications for Cancer SurvivorsIdentifying routinely measured patient characteristics which may contribute to an individual’s CIPN risk profile could assist with informing treatment decisions.
Journal of Cancer Survivorship – Springer Journals
Published: Apr 1, 2022
Keywords: Chemotherapy; Neuropathy; Risk factors; Obesity; Body mass index
Access the full text.
Sign up today, get DeepDyve free for 14 days.